bell
The current prices are delayed by 15 mins, login to check live prices.
Glaxosmithkline Pharmaceuticals Ltd share price logo

Glaxosmithkline Pharmaceuticals Ltd

(GLAXO)

₹2411.81.78%

as on 04:01PM, 22 Nov 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Glaxosmithkline Pharmaceuticals Ltd Analyst Rating

based on 4 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 4 analysts offering long term price targets for Glaxosmithkline Pharmaceuticals Ltd. An average target of ₹2914.5

Source: S&P Global Market Intelligence

Glaxosmithkline Pharmaceuticals Ltd Share analysis

Glaxosmithkline Pharmaceuticals Ltd price forecast by 4 analysts

Upside of20.84%

High

₹3250

Target

₹2914.50

Low

₹2550

Glaxosmithkline Pharmaceuticals Ltd target price ₹2914.5, a slight upside of 20.84% compared to current price of ₹2411.8. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Glaxosmithkline Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹2,350
    ₹2,439.9
  • 52 Week's Low

    52 Week's High

    ₹1,577
    ₹3,088
1 Month Return-8.31 %
3 Month Return-18.08 %
1 Year Return+ 43.2 %
Previous Close₹2,369.65
Open₹2,389.00
Volume2.89L
Upper Circuit-
Lower Circuit-
Market Cap₹40,143.30Cr

Glaxosmithkline Pharmaceuticals Ltd Key Statistics

P/E Ratio51.66
PEG Ratio5.33
Market Cap₹40,143.30 Cr
P/B Ratio18.45
EPS34.83
Dividend Yield1.65
SectorPharmaceuticals
ROE36.83

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹40,143.30 Cr9.01%0.56₹589 Cr₹3,453 Cr
BUY₹13,994.64 Cr-2.57%0.52₹602 Cr₹2,851 Cr
BUY₹71,484.51 Cr35.55%0.56₹3,168 Cr₹29,001 Cr
HOLD₹94,993.52 Cr53.94%0.64₹3,854 Cr₹19,547 Cr
BUY₹57,618.74 Cr23.66%0.53NANA

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Share Price: ₹2411.80 per share as on 22 Nov, 2024 04:01 PM
Market Capitalisation: ₹40,143.30Cr as of today
Revenue: ₹1,010.77Cr as on September 2024 (Q3 24)
Net Profit: ₹252.50Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad
OrganisationGlaxosmithkline Pharmaceuticals Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glaxosmithkline Pharmaceuticals Ltd

  • Glaxo Pharma Reports Strong Q2FY25 Performance - 15 Nov, 2024

    In Q2FY25, Glaxo Pharma surpassed expectations, driven by robust growth in specialty and pediatric vaccine segments, despite challenges in generics. Management anticipates continued momentum in pediatric vaccines, with a 13% YoY increase in the first half of FY25.

  • GSK Celebrates 100 Years in India - 12 Nov, 2024

    GSK marks a century in India, reflecting on its journey from antibiotics to vaccines. The company emphasizes innovation and adaptation in a challenging ecosystem.

  • GSK Pharma Declares Special Interim Dividend - 04 Nov, 2024

    GSK Pharma has set November 7, 2024, as the record date for a special interim dividend of ₹12 per equity share, reflecting its strong financial position and commitment to shareholders.

  • GlaxoSmithKline Announces Special Interim Dividend - 03 Nov, 2024

    GlaxoSmithKline Pharmaceuticals Ltd's Board has recommended a special interim dividend of Rs. 12 per share. The company reported a 5% increase in quarterly revenue, surpassing Rs 1000 crores, and a 15% rise in profit after tax to Rs 249 crores. For the half-year ending September 30, 2024, revenue grew by 7%, with EBITDA margins at 30%. This announcement coincides with the company's centenary year in India.

  • GSK Pharma Reports Strong Q2 Earnings and Dividend - 30 Oct, 2024

    GlaxoSmithKline Pharmaceuticals reported a 5.53% revenue increase and a 15.59% net profit growth in Q2 FY25. The stock surged over 3% following the announcement of a special interim dividend of Rs 12 per share, reflecting strong performance and market confidence.

  • GlaxoSmithKline Reports Strong Q2 Growth and Dividend - 29 Oct, 2024

    GlaxoSmithKline Pharmaceuticals announced a 16% increase in Q2 net profit to Rs 252 crore, driven by robust sales. The company declared a special interim dividend of Rs 12 per share, celebrating its centenary year in India.

Insights on Glaxosmithkline Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 850.29 Cr → 1.05K Cr (in ₹), with an average increase of 19.0% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.02% to 4.36% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 182.33 Cr → 252.5 Cr (in ₹), with an average increase of 27.8% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 4.71% to 4.98% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 128.6% return, outperforming this stock by 77.8%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 62.6% return, outperforming this stock by 19.4%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 13.48% to 13.30% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GLAXO stock has moved down by -8.3%

Glaxosmithkline Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹956.99Cr (-)₹805.26Cr (↓15.85%)₹929.80Cr (↑15.47%)₹814.65Cr (↓12.38%)₹1,010.77Cr (↑24.07%)
Net Income₹217.51Cr (-)₹45.72Cr (↓78.98%)₹194.48Cr (↑325.37%)₹182.33Cr (↓6.25%)₹252.50Cr (↑38.49%)
Net Profit Margin22.73% (-)5.68% (↓75.01%)20.92% (↑268.31%)22.38% (↑6.98%)24.98% (↑11.62%)
Value in ₹ crore
Details2021202220232024
Total Assets₹3,112.65Cr (-)₹4,641.49Cr (↑49.12%)₹3,345.90Cr (↓27.91%)₹3,564.93Cr (↑6.55%)
Total Liabilities₹1,615.53Cr (-)₹1,963.87Cr (↑21.56%)₹1,592.90Cr (↓18.89%)₹1,780.83Cr (↑11.80%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹490.97Cr (-)₹594.87Cr (↑21.16%)₹819.79Cr (↑37.81%)₹487.94Cr (↓40.48%)₹578.94Cr (↑18.65%)

Index Inclusions

S&P BSE Quality

₹1,797.46

1.98 (34.82%)

BSE Mid-Cap

₹45,029.22

1.26 (561.23%)

S&P BSE 150 MidCap

₹15,488.33

1.32 (201.63%)

S&P BSE 400 MidSmallCap

₹11,760.86

1.18 (137.44%)

Nifty LargeMidcap 250

₹15,487.30

1.65 (250.9%)

Nifty MidSmallcap 400

₹19,196.45

1.09 (206.7%)

BSE 500

₹35,009.77

1.89 (648.36%)

BSE Healthcare

₹42,969.55

1.23 (522.48%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Nifty Midcap 150

₹20,412.65

1.15 (231.75%)

Nifty 500

₹22,225.55

1.85 (404.7%)

BSE 200

₹10,937.66

2.01 (215.63%)

S&P BSE 250 LargeMidCap

₹10,372.42

1.99 (202.64%)

Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
0.00
Foreign Institutions
4.36%
8.59
Mutual Funds
4.98%
5.75
Retail Investors
13.3%
-1.33
Others
2.36%
-15.61

Glaxosmithkline Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Book Value Per Share (₹)107.4787.26157.19102.79104.93
Details20202021202220232024
Earning Per Share (₹)5.521.14100.0436.0534.83
Details20202021202220232024
Return On Equity %9.928.4980.4527.4336.83
Details20202021202220232024
Return On Assets %2.9611.5136.5118.2516.55

Glaxosmithkline Pharmaceuticals Ltd Valuation

Glaxosmithkline Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-81.64x)

December 28, 2020

Today (51.66x)

November 22, 2024

Industry (54.77x)

November 22, 2024

Highest (333.07x)

September 15, 2020

LowHigh

Glaxosmithkline Pharmaceuticals Ltd Earnings and Dividends

  • Glaxosmithkline Pharmaceuticals Ltd Earnings Results

    Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 16.09% since last year same period to ₹252.50Cr in the Q2 2024-2025. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated 38.49% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Glaxosmithkline Pharmaceuticals Ltd Dividends October,2024

    In the quarter ending September 2024, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹12 - translating a dividend yield of 1.82%.

    Read More about Dividends

Glaxosmithkline Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Glaxosmithkline Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Glaxosmithkline Pharmaceuticals Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glaxosmithkline Pharmaceuticals Ltd shares.

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price today is ₹2411.8

Glaxosmithkline Pharmaceuticals Ltd is listed on NSE

Glaxosmithkline Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Glaxosmithkline Pharmaceuticals Ltd is ₹2439.9.
  • Today’s lowest price of Glaxosmithkline Pharmaceuticals Ltd is ₹2350.

PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 51.66

PE ratio = Glaxosmithkline Pharmaceuticals Ltd Market price per share / Glaxosmithkline Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is 2.89L.

Today’s market capitalisation of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is ₹40143.3Cr.

Glaxosmithkline Pharmaceuticals Ltd(GLAXOPrice
52 Week High
₹3088
52 Week Low
₹1577

Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2411.8. It is down -21.90% from its 52 Week High price of ₹3088

Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2411.8. It is up 52.94% from its 52 Week Low price of ₹1577

Glaxosmithkline Pharmaceuticals Ltd(GLAXOReturns
1 Day Returns
42.15%
1 Month Returns
-8.31%
3 Month Returns
-18.08%
1 Year Returns
43.2%